Prelude Capital Management, LLC Lineage Cell Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$1.2 - $1.53 $20,025 - $25,532
16,688 New
16,688 $25,000
Q3 2022

Nov 14, 2022
BUY
$1.13 - $1.77 $12,955 - $20,293
11,465 New
11,465 $13,000
Q2 2021

Aug 16, 2021
SELL
$2.17 - $3.0 $38,037 - $52,587
-17,529 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$1.77 - $3.1 $31,026 - $54,339
17,529 New
17,529 $41,000

Others Institutions Holding LCTX

# of Institutions
121
Shares Held
94.2M
Call Options Held
63.8K
Put Options Held
1K
View Full List

About Lineage Cell Therapeutics, Inc.

LCTX Quotes by TradingView
  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $84.9M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email